[ET Net News Agency, 8 October 2021] KINTOR PHARMA-B (09939) rose 9.75% to HK$45.6.
It hits an intra-day high of HK$45.8, and an intra-day low of HK$41.55. The total shares
traded was 972,000, with a value of HK$42.44m. The active buy/sell ratio is 58:42, with
net buying turnover of HK$5.97m. CHINA INNOVATION MARKET SER accounts for greatest net
responsive buying turnover of HK$6.4m, with volume weighted average price of HK$43.912.
MORGAN STANLEY HK SEC accounts for greatest net responsive selling turnover of HK$1.82m,
with volume weighted average price of HK$44.675. The stock has risen a combined 22.42%
over the past 3 consecutive trading days.
The Hang Seng Index now rose 144 points, or 0.59% to 24,846; the Hang Seng China
Enterprises Index now rose 74 points, or 0.86% to 8,787; the Hang Seng TECH Index now rose
59 points, or 0.97% to 6,231; with an overall turnover of HK$29.02b.
The SSE Composite Index now rose 31 points, or 0.87% to 3,599, with an overall turnover
of RMB132.84b.
The SZSE Component Index now rose 175 points, or 1.23% to 14,484, with an overall
turnover of RMB74.89b.

Basic Information
=================

-----------------------------------
Nominal 45.600 % Chg +9.75%
High 45.800 Low 41.550
Shares Tr 972,000 Turnover 42.44m
10-D SMA 46.620 %H.V 168.076
20-D SMA 59.840 VWAP 43.661
50-D SMA 68.104 RSI14 37.303
-----------------------------------
Status: Active buy/sell ratio is 58:42, with net buying turnover of HK$5.97m, rising a
combined 22.42% over the past 3 consecutive trading days

Performance of stocks in the same sector or of relevance
========================================================

Stock (Code) Price (HK$) Change (%)
-----------------------------------------------
KINTOR PHARMA-B (09939) 45.60 +9.75
GENSCRIPT BIO (01548) 32.15 +4.05
INNOVENT BIO (01801) 77.45 +1.71
JXR (01951) 12.36 +0.65
BRII-B (02137) 29.40 +2.08
WUXI BIO (02269) 118.80 -0.17
TIGERMED (03347) 166.90 +4.05
BEIGENE (06160) 215.60 +3.65
CANSINOBIO-B (06185) 236.40 +4.23
AKESO-B (09926) 41.10 +0.98
-----------------------------------------------
(ed)